After over 30 years examining abnormalities in the number and properties of D2 receptors in the brains of individuals who died with schizophrenia, Dr. Philip Seeman started Clera Inc. in 2002. The goal of the company is to design, test, and launch better antipsychotics, antidepressants and antiparkinson medications.

Clera now has discoveries on a series of antipsychotics, antidepressants and antiparkinson medications. The present emphasis is to test various therapeutic approaches clinically.

In particular, Clera is testing new methods for enhancing antidepressant treatment, and for enhancing antiparkinson treatment.

Clera has discovered a common basis in the D2 receptor to all forms of psychosis, whether the psychosis arises from street drugs, from Alzheimer’s disease, or from genetic mutations associated with schizophrenia. Clera is testing a new antipsychotic, based on their “fast-off” principle, specifically designed to prevent psychosis that frequently occurs during antiparkinson treatment.

Clera is introducing a new way of treating psychotic patients such as to reduce the risk of tardive dyskinesia, a side-effect that can ordinarily emerge after long-term treatment with traditional antipsychotics.

The Clera approach emphasizes the advantage of returning to basics before forging new avenues of treatment. 

The goal of science is humility.